Brain, Vol. 119, No. 5, 1461-1469, 1996
© 1996 Guarantors of Brain
research-article |
Low affinity NGF receptor expression in CMT1 A nerve biopsies of different disease stages
1Department of Neurolog, Heinrich-Heine-University Duesseldorf, Germanynds 2Institute of Neurology, University Hospital Nijmegen Nijmegen, Netherlands
Correspondence to:
C. O. Hanemann MD, Molecular Neurobiology Laboratory, Department of Neurology, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany
Duplication of the gene for the peripheral myelin protein 22 (PMP22) is the most common cause for Charcot-Marie-Tooth neuropathy type la (CMTIA) neuropathy. In early stages of the disease PMP22 is overexpressed in nerve biopsies from CMTIA patients. Recent studies with genetically modified Schwann cells have demonstrated that the altered expression of PMP22 modulates cell growth. Thus we hypothesized that elevated expression of PMP22 at the beginning of the disease might alter Schwann cell differentiation and phenotype. In this study we investigated Schwann cell phenotype in different stages of CMTIA neuropathy using antibodies to established Schwann cell markers. We found a pathological expression of low affinity nerve growth factor receptor (LNGF-R—also referred to in the literature as p75) in numerous Schwann cells of young CMTIA patients with almost normal myelin thickness and very few onion bulbs. During further progression of the disease, when Schwann cells began to form onion bulbs, we observed an intense LNGF-R immunoreactivity in all layers of the onion bulbs. In the most advanced stages of the disease, characterized by massive onion bulb formation, no LNGF-R immunoreactivity was shown. In age-matched control nerves LNGF-R staining was barely detectable. Furthermore, onion bulbs seen in patients with chronic idiopathic polyneuropathy (CIDP) were always negative for LNGF-R. In addition, at all CMTIA disease stages analysed, LNGF-R-positive Schwann cells were glial fibrillary acidic protein (GFAP) negative. Immunostaining with an antibody to the proliferation marker, proliferating cellular nuclear antigen (PCNA) indicated Schwann cell proliferation when onion bulb formation was well developed. In conclusion, we describe a disease stage-dependent altered Schwann cell phenotype in CMTIA neuropathy, which could be a direct consequence of the PMP22 overexpression on Schwann cell growth behaviour or, less likely, a secondary phenomenon related to myelin loss.
cell differentiation; CMTIA neuropathy; immunohistochemistry; low affinity NGF receptor; PMP22; Schwann cells
Received December 8, 1995. Revised April 14, 1996. Accepted June 1, 1996.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Schneider, F. Bosse, D. D'Urso, H.-W. Muller, M. W. Sereda, K.-A. Nave, A. Niehaus, T. Kempf, M. Schnolzer, and J. Trotter The AN2 Protein Is a Novel Marker for the Schwann Cell Lineage Expressed by Immature and Nonmyelinating Schwann Cells J. Neurosci., February 1, 2001; 21(3): 920 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Niemann, M. W. Sereda, U. Suter, I. R. Griffiths, and K.-A. Nave Uncoupling of Myelin Assembly and Schwann Cell Differentiation by Transgenic Overexpression of Peripheral Myelin Protein 22 J. Neurosci., June 1, 2000; 20(11): 4120 - 4128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. O. Hanemann, D. D'Urso, A. A. W. M. Gabreels-Festen, and H. W. Muller Mutation-dependent alteration in cellular distribution of peripheral myelin protein 22 in nerve biopsies from Charcot-Marie-Tooth type 1A Brain, May 1, 2000; 123(5): 1001 - 1006. [Abstract] [Full Text] [PDF]
|
|